24 Jan 05
For people with migraine, today’s world is a better world than the one their parents knew. The last 15 years have seen major advances, giving us not only a much clearer understanding of the disorder but also considerably more effective therapies. Treatments exist that – if made available and used in the right way – can substantially relieve the majority of people affected by migraine.
21 Jan 05
The increasing incidence of surgical site infections (SSIs) among hospital patients in Europe has led to a call to action for cost-effective preventative measures to be put in place by hospitals, to help minimize the risk of infection and the cost impact on healthcare systems. A consensus paper, developed by a number of leading healthcare experts in Europe and published today in the International Wound Journal, indicates the scale of the problem and the estimated financial impact on the health
Wound Healing Research Unit
17 Jan 05
Epilepsy is a common condition in the UK, with an incidence of approximately 80 cases per 100,000 population per year, and a prevalence of 5–10 cases per 1000. Yet, despite this high prevalence, it remains a stigmatising condition, with occupational and social disadvantages imposed on the individual. Epilepsy is difficult to diagnose, requiring a detailed history, and is complex to manage.
Csf Medical Communications
17 Jan 05
Knowledge will be pooled and ideas investigated through focused discussion topics:
* What approach to take to target validation?
* Establishing the true impact of off-target effects
* Unravelling the different pathways
* What can delivery systems achieve?
* What are the pros and cons of different chemical modification?
* Addressing pharmacokinetics and modification issues for each disease
What do I need for clinical testing of an siRNA compound?
17 Jan 05
It is estimated that there are more than 38 million people in the seven major markets with diabetes and this figure is set to rise to 50 million in 2012. However, despite this vast potential patient population, low diagnosis rates, the chronic nature of the disease, the need for combination therapy, the lack of an oral antidiabetic agent offering effective long-term therapy and the association of injectable therapies with poor patient compliance mean that a broad spectrum of unmet needs exists.
13 Jan 05
Morgan Levy (formally E-Focus Resourcing) has pleasure in announcing that we have re-branded to Morgan Levy with effect from January 2005.
GARY M BRITNELL
04 Jan 05
The development of dendritic cell vaccines to fight cancer is an attractive therapeutic approach. Usually this strategy involves pre-pulsing dendritic cells with cancer antigen and maturing them ex vivo prior to administering them to patients. Limitations to this approach include the cumbersome nature of antigen loading and maturation and the limited immunogenicity of the cells. The company BioVEX have successfully developed viruses to load dendritic cells with antigen. Researchers from Baylor h
20 Dec 04
The outlook for hepatocellular carcinoma (HCC) sufferers is bleak - current medication has a five-year survival rate for those with liver cancer of less than 5% in the developed world and even lower in developing countries. However, patients in trials of a new drug called Sorafenib have seen their survival times double. Datamonitor's Dr Lorna Fern investigates...
15 Dec 04
Despite the advances made in healthcare there remains a startling amount of the world’s population that is unable to gain access to even the most basic services and treatments. This is an issue that has attracted considerable media coverage and represents a challenge for all those involved in healthcare to overcome.
Dr Faiz Kermani
14 Dec 04
Britain’s hospital patients, led by Claire Rayner, today called for healthcare professionals to get behind the UK’s first ever Clean Hospitals Summit, planned for April 14-15, 2005.
Anna Harris/ Alan Murray
13 Dec 04
This report introduces the emerging field of oncolytic viruses and the various benefits that oncolytic virology can offer in the treatment of cancer. Clinical data suggest that oncolytic viruses may offer therapeutic advantages over existing cancer therapies such as chemotherapy and radiation and may even act synergistically with these conventional approaches. This report evaluates preclinical and clinical data on oncolytic viruses that have entered the clinic.
10 Dec 04
The recent announcement by the FDA's associate director for science and medicine that sales of GlaxoSmithKline's asthma drug Serevent should be restricted, or halted, led to an estimated 3.8% fall in the company's share price. However, Datamonitor's Laura Harris comments that, with Seretide accounting for the majority of GSK's asthma sales, the panic may be premature.
09 Dec 04
Distinct, original scientific and business content focusing on R&D productivity presented by an international line-up of industry experts. Drug Discovery Technology® Europe is known for its high standard of speakers and coherent case studies, which guarantee that delegates grasp an understanding of the pressing issues that affect their industry. This year, for the first time, the conference will be co-located with two other events, InfoTechPharma® 2005 and PharmaSolutions Expo.
09 Dec 04
The premier annual global forum for top-level Pharma IT executives, examining innovative IT systems and applications to support and accelerate R&D. This exciting programme is the result of research with well over 100 industry professionals and the InfoTechPharma® scientific advisory board. The programme contains only original content tackling key subjects that are currently impacting R&D in pharma and biotech. The format of this years conference will provide an environment that will facilitate i
09 Dec 04
PharmaSolutions Expo is a unique event gathering the drug discovery, drug development and informatics communities under one roof. Meet face-to-face with solution providers and make comparisons of new technologies. This exhibition will showcase the latest tools and solutions for R&D scientists and Pharma IT professionals. Free exhibition features include: dedicated poster areas and “meet the author” poster sessions, free seminars, lunchtime roundtable discussion groups, biotech start-up presentat
09 Dec 04
Now, more than ever, pharma marketing operations are being required to demonstrate that they are adding value and delivering measurable return on investment. With this in mind, Freedman International surveyed delegates who attended the eyeforpharma ‘Marketing ROI for Pharma’ conference using a unique self-assessment tool to find out, “How do you fare in terms of the overall effectiveness of your marketing operations?”
08 Dec 04
At a recent hearing into the Vioxx affair, the FDA's Dr David Graham named five drugs that he considers too dangerous to be on the market. However, in his testimony, Dr Graham also cited Sanofi-Aventis' Arava as a drug he has recommended be withdrawn. Unlike the other five drugs, Arava has largely escaped the media spotlight, but there may yet be some tough questions asked about its safety.
30 Nov 04
The conference will present the latest research and advances on new techniques in drug discovery. As well as presentations from some of the top authorities in the field, the exhibition will allow you to view the latest technologies from leading suppliers within the industry. An unmissable event for those wishing to keep abreast of new developments.
29 Nov 04
Unique intelligence from eyeforpharma: 'Barriers, best practices and measuring ROI for patient compliance programmes'
26 Nov 04
Study data presented at a major recent conference has demonstrated that Wyeth's novel antibacterial tigecycline acts against drug-resistant pathogens in some serious bacterial infections, including MRSA. While Wyeth will have to work hard to establish tigecycline in this competitive area, its encouraging tolerability profile could give it a useful advantage over existing treatments.
24 Nov 04
The recent calamity surrounding Vioxx is one example of what can go awry in the pharmaceutical industry. US drug company Merck (NUSE: MRK) was forced to withdraw this painkiller after in-house studies showed that patients could be at greater risk of suffering heart attacks.
David Kuo (TMFDragon)
19 Nov 04
Influenza is a global disease which imposes a huge medical and economic burden inevery country of the world. The UK is no exception with one caveat - the virus is probably monitored and tracked more in the UK than any other country around the globe. Over the years, GPs have played a leading role in estimating the quantitative impact of influenza. This started with the pioneering work of William Pickles in the Wensleydale villages and continued with Edgar Hope-Simpson in Cirencester.
17 Nov 04
School can be a difficult place at the best of times, however for the 20 million plus children in the seven major pharmaceutical markets that suffer from attention deficit and hyperactivity disorder (ADHD), it can be especially troubling. This exacerbated by the fact that many patients aren't receiving the best available treatment, according to new research from Datamonitor.
09 Nov 04
Over the past 30 years, numerous clinical trials evaluating a variety of different classes of drugs have conclusively shown the benefit of blood pressure reduction in reducing the risk of strokes and cardiovascular mortality. Moreover, such trials have clearly demonstrated that blood pressure is unlikely to be controlled with a single drug and often two or more therapies are required to achieve blood pressure targets.
05 Nov 04
Altana has announced the delay of its US application for Daxas until late 2005 due to clinical trial enrolment taking longer than originally anticipated. The news will be of further concern to the company's investors, coming on the back of the recent announcement that another of its respiratory drugs, Alvesco, failed to win full FDA approval.
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.